文献リスト

1) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会誌. 2005; 94: 188-203

2) 柏木厚典. メタボリックシンドローム Over View: 日本医師会雑誌. 2007: 136(特別号): S2-13

3) Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007; 46: 1091-100

4) 山内敏正, 植木浩二郎, 門脇 孝. 内臓肥満に対する薬物治療. 医学のあゆみ NAFLDのすべて. 2006; 144-9

5) 谷川久一. 肝を中心とする代謝調節異常. 医学のあゆみ NAFLDのすべて. 2006; 4-9

6) 西村治男. 肥満とNAFLD, 医学のあゆみ NAFLDのすべて. 2006, 44-8

7) Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143: 722-8

8) Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 14: 1579-84

9) 岡 芳知. インスリン抵抗性. 日本医師会雑誌. 2007; 136(特別号): S81-3

10) Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132: 2169-80

11) 岡上 武, 田村信司, 坪内博仁, 他. 肝臓学会, 編. NASH・NAFDLの診療ガイド. 東京: 文光堂; 2006

12) Amarapurkar DN, Hashimoto E, Lesmana LA, et al. Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences？ J Gastroenterol Hepatol. 2007; 22: 788-93

13) 橋本悦子. NASHの診断基準. 日本臨牀. 2006; 64: 1025-32

14) 橋本悦子. 病理診断. In: 西原利治, 編. NASH診療ハンドブック. 東京: 中外医学社; 2007. p. 34-47

15) Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Related Articles: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21

16) Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005; 42: 641-9

17) Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004; 40: 475-83

18) Farrell GC, Larter GZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006; 43 suppl 1: S99-112

19) Kaneda H, Hashimoto E, Yatsuji S, et al. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006; 21: 1459-65

20) Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 34

21) Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128: 1898-906

22) 橋本悦子. NASHの経過と予後. 臨床消化器内科 2007. in press

23) Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42: 132-8

24) Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44; 865-73

25) Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterol. 2005; 129: 113-21

26) Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005; 33: 72-6

27) Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatoloty. 2006; 43: 682-9

28) Ratziu V, Bonyhay L, Martino VD, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002; 35: 1485-93

29) Yoshioka Y, Hashimoto E, Yatsuji K, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol. 2004; 39: 1215-8

30) Yatsuji S, Hashimoto E, Kaneda H, et al. Characteristic features and risk factors for hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2005; 42 Suppl 1: 625A

31) Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2: 1107-15

32) Promrat K, Lutchman G, Uwaifo G, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39: 188-96

33) Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297-307

34) Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-90

35) Tokushige K, Hashimoto E, et al. Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. Hepatol Res. 2007; 37: 872-7

36) 兵庫秀幸, 岩本佳子, 有広光司, 他. コレステロール合成阻害剤による非アルコール性脂肪性肝炎に対する抗炎症・抗線維化作用. 肝臓. 2005; 36: 292-3

37) Kawanaka M, Mahmood S, Nuyama G, et al. Control of oxidative stress and reduction in biochemical markers by vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res. 2004; 29: 39-41

38) Lindor KD, Kowdley KV, Hearhcote EJ, et al. Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004; 39: 770-8

39) Yamamoto M, Iwasa M, Iwata K, et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007; 22: 498-503

40) Dufour JF, Oneta CM, Gonvers JA, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006; 4: 1537-43

41) Yokohama S, Yoneda M, et al. Therapeutic efficacy of an angiotensin ll receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004; 40: 1222-5

42) Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005; 129: 1937-43

43) Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007; 27: 607-11

44) Clouston AD, Jonsson JR, Powell EE, et al. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007; 11: 173-89

45) Leandro G, Mangia A, Hui J, et al. HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006; 130: 1636-42

46) Bjornsson E, Angulo P. Hepatitis C and steatosis. Archives of Medical Research. 2007; 38: 621-7

47) Kim KH, Shin H-J, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ. Gastoroenterology. 2007; 132: 1955-67

48) Cram CJ, Babiuk LA, Liu Quang, et al. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: Genotype-3a core has a stronger effect than genotype-1b core. J Hepatology. 2007; 46: 999-1008

49) Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006; 43: 1177-86

50) Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007; 45: 80-7

51) Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004; 126: 840-8

52) Calle EE, Rodriguez C, Walker-Thumond K, et al. Overweight, obesity and mortality from cancer in a prospectively studies cohort of US adults. N Engl J Med. 2003; 348: 1625-38

53) El-Serag HB, Tran T, Everhart JE. Diabetes increses the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterol. 2004; 126: 460-8

54) Muto Y, Sato S, Watanabe A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006; 35: 204-14

55) Pekow JR, Bhan AK, Zheng Hut, et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-reltated cirrhosis. Cancer. 2007; 109: 2490-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp